9 results about "Liposome Vesicle" patented technology

The invention provides a biomimetic enzyme functional composite membrane constructed by microfluidics and application of the biomimetic enzyme functional composite membrane in removal of water pollutants. According to the composite membrane, lipidosome vesicles embedded with laccase molecules are prepared through a microfluidic method, a functional coating is formed by sodium alginate, and the functional coating and a porous PVDF supporting membrane are compounded to form a multi-layer membrane structure. The prepared biomimetic membrane simulates the gradient structure of a biological water channel, achieves the synergistic effect of enzyme catalytic degradation and physical filtration, has high selectivity and high permeation flux, and solves the technical problem that'flux-selectivity 'of a traditional membrane is difficult to consider. The membrane material is derived from natural renewable resources, the preparation process is green and environment-friendly, and the membrane shows efficient purification capacity in the aspect of removing heavy metal ions and organic dye pollutants and has excellent anti-pollution and self-cleaning characteristics.

The invention provides a liposome for protecting mitochondrial vesicles of mesenchymal stem cells as well as a preparation method and application of the liposome, and belongs to the technical field of liposome preparation. The liposome comprises a lipid membrane and a mitochondrial protective agent located in the lipid membrane, preparation raw materials of the lipid membrane comprise DOPC, DOTAP, cholesterol and DSPE-PEG2000, and preparation raw materials of the mitochondrial protective agent comprise human serum albumin, trehalose, glutathione, tryptophan and the like. The liposome has good biocompatibility and safety, and immunogenicity and toxicity risks are reduced. After the lipidosome is fused into the mitochondrial vesicles, the structural integrity, the membrane fluidity and the functional activity of mitochondria can be effectively maintained, mitochondrial swelling and collapse are reduced, and the mitochondrial membrane potential is maintained; the liposome vesicles can be stably stored for 6-8 hours at 25 DEG C, and the short-distance transportation requirement is met. The preparation raw materials of the liposome are low in cost, the preparation method is simple and easy to implement, and the liposome is suitable for large-scale production.

The invention relates to the technical field of sterilization and antifogging, in particular to a microsphere-based antibacterial and antifogging additive, a preparation method thereof, a multifunctional coating and application. The microsphere-based antibacterial and antifogging additive is a liposome vesicle microsphere, and the liposome vesicle microsphere is prepared from an oil-phase raw material and a water-phase raw material; the oil phase raw material comprises one or more of distearoyl phosphatidylcholine, hydrogenated lecithin and cholesterol; the water-phase raw material is a mixture of polyhexamethylene biguanide, polyethyleneimine and benzalkonium chloride; in the water phase raw material, the content of the polyhexamethylene biguanide is 25wt%-45wt%. By optimizing the formula of the microspheres, the efficiency and effect of killing nucleic acid can be remarkably improved, and the fog-resistant and anti-fog effects are achieved.

This invention discloses a method for determining the encapsulation efficiency of amphotericin B liposomes for injection, comprising the following steps: separating the amphotericin B liposome solution for injection using solid-phase extraction adsorption to obtain an encapsulated drug solution and a free drug solution; and determining the drug mass concentration C in the encapsulated drug solution using HPLC. 包封 Drug mass concentration C in free drug solution 游离 And the total drug concentration C in the amphotericin B liposome solution before separation 总 The encapsulation efficiency and recovery rate of amphotericin B liposomes were calculated. This invention utilizes a macroporous copolymer of divinylbenzene and N-vinylpyrrolidone as the adsorbent in a solid-phase extraction adsorption method. Its macroporous structure provides ample adsorption sites while avoiding physical compression and damage to the liposome vesicles. This method achieves the separation of free amphotericin B liposomes from the encapsulated drug, exhibiting good reproducibility, high accuracy, simple operation, and high recovery rate.

The invention discloses a non-invasive pulmonary alveolar targeting carrier capable of being inhaled through a respiratory tract and a preparation method and application of the non-invasive pulmonary alveolar targeting carrier. The non-invasive pulmonary alveolar targeting carrier is mainly characterized in that a PEG grafted enzyme response substrate (the enzyme response substrate is pulmonary alveolar surface active protein SP-B / SP-C / SP-D) is synthesized firstly, and then the PEG grafted enzyme response substrate is used for modifying liposome vesicles formed by a liposome main body and cholesterol; animal-derived or synthetic alveolar surfactants are loaded in the vesicles, and the average particle size of the vesicles is 50-1000 nm. The liposome vesicle overcomes the defect that in the prior art, alveolar surfactants or liposome vesicles are difficult to reach alveolar delivery drugs in a targeted mode, alveolar active substances can be efficiently delivered, and the liposome vesicles have good application prospects.

The invention discloses a nano material for inhibiting aseptic inflammation as well as a preparation method and application of the nano material. The nano material is hybrid liposome nano vesicles modified by a platelet membrane, and the mass ratio of protein to lipid is 1: 2. The nano vesicles are loaded with sylvite compounds, can target in-vivo tissue injury parts, release potassium ions under the action of ultrasound, realize intracellular pH regulation and control through hydrogen-potassium exchange, and inhibit aseptic inflammation. The hybrid liposome is formed by mixing phospholipid and cholesterol, and the potassium salt compound is potassium carbonate or potassium bicarbonate. The preparation method comprises the following steps: preparing a hybrid liposome membrane and a platelet membrane, respectively adding a sylvite compound solution to carry out ultrasonic hydration and resuspension washing, preparing hybrid liposome vesicles and platelet membrane vesicles entrapped with sylvite compounds, and carrying out ultrasonic treatment, size stabilization and dialysis to obtain the platelet membrane modified hybrid liposome nano-vesicles. Inflammation can be inhibited in the early stage of injury, and side effects of traditional drugs are avoided.

The invention belongs to the technical field of anti-oxidation systems, and discloses a bionic high-biological-activity anti-oxidation defense lipidosome system, application and a construction method.The bionic high-biological-activity anti-oxidation defense lipidosome system is characterized in that bionic means is adopted, and elements of an anti-oxidation defense system in biological cells, such as simulated antioxidant enzymes, water-soluble antioxidant factors and fat-soluble antioxidant factors, are combined into a whole in a bionic manner; layered entrapment is carried out in the form of liposome vesicles, and the center of the system is a water-soluble antioxidant factor; the outer side of the water-soluble antioxidant factor is coated with a lipidosome double-layer structure, and the lipidosome double-layer structure is embedded with the fat-soluble antioxidant factor; a combination of chitosan and Pt nanoclusters is arranged on the outer side of the liposome double-layer structure; the system is applied to preparation of smearing type medicines for resisting oxidative stress inflammation or medicines for improving systemic oxidative stress inflammation diseases. The system constructed by the invention has synergistic oxidation resistance, can effectively remove various active oxygen and active nitrogen, can be used for protecting cell components from oxidative damage, and can promote wound healing.

The present invention discloses a method for preparing liposome-encapsulated targeted protein degradation nanoparticles and their application. The present invention blends a polymetformin-based protein degradation targeted chimera with hyaluronic acid to form polyprotein degradation targeted chimera nanoparticles through electrostatic adsorption. The liposome vesicles are then blended with the polyprotein degradation targeted chimera nanoparticles and co-extruded to obtain liposome-encapsulated targeted protein degradation nanoparticles. The liposome-encapsulated targeted protein degradation nanoparticles designed by the present invention can overcome the hook effect of the protein degradation targeted chimera in tumor cells and achieve long-term circulation of the protein degradation targeted chimera in the body, thereby maximizing the in vivo utilization of the protein degradation targeted chimera and enhancing the anti-tumor effect.

The invention discloses an inhalation type drug delivery system with a phospholipid-protein surface active structure and application of the inhalation type drug delivery system. The inhalation type drug delivery system comprises liposome vesicles modified by PEG (polyethylene glycol)-angiotensin converting enzyme II substrate polypeptide, and alveolar surface active substances are loaded in the liposome vesicles. According to the inhalation type drug delivery system, the drug can be delivered into the lung in an aerosol inhalation mode and can be evenly distributed in pulmonary alveoli, pulmonary alveoli development can be effectively promoted, the ventilation function can be improved, and the inhalation type drug delivery system has a good curative effect in premature infant pulmonary dysplasia treatment. According to the inhalation type pulmonary alveolar surface active substance delivery system, an existing administration mode that liquid drops are dropped through a trachea cannula is changed, and the problems that segmental pulmonary atelectasis, asphyxia and the like are possibly caused are solved. The inhalation type drug delivery system can be stably and efficiently degraded when reaching the pulmonary alveoli, and is safe and low in toxicity.